Drugs / 123-I-MIP-1095
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00712829 | May 2008 → Jan 2009 | prostate cancer | Molecular Insight Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 123-I-MIP-1095 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00712829 ↗ |
| Known as | MIP-1095 I-123 | ChEMBL registry synonym — accepted as the source's own label CHEMBL456029 ↗ |
| Action | Inhibit | “Small Molecule Inhibitors of Prostate Specific Membrane Antigen” NCT00712829 ↗ |
| Modality | Small molecule | “Small Molecule Inhibitors of Prostate Specific Membrane Antigen” NCT00712829 ↗ |
| Route | Intravenous | “10 mCi intravenous injection given one time during the study” NCT00712829 ↗ |